Ahchiabor personal page - To The Moon

Ahchiabor

No personal profile

35Follow

2Followers

0Topic

0Badge

2021-06-15

Like and comment pls

Fed Poised to Crawl Onto ‘Knife Edge’ to Rein In Record Largesse

2021-06-10

??

1stdibs.com, Inc. Announces Pricing of Initial Public Offering

2021-06-10

Pls like and comment ?

U.S. stocks end lower ahead of inflation report

2021-06-08

Comment pls!

S&P closes nominally lower as investors wait for a catalyst

2021-06-08

Happy to read this news

Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3579400009595208","uuid":"3579400009595208","gmtCreate":1616307356355,"gmtModify":1616307356355,"name":"Ahchiabor","pinyin":"ahchiabor","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":35,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.10","exceedPercentage":"60.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.88%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":187674824,"gmtCreate":1623753904268,"gmtModify":1704210577461,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/187674824","repostId":"1142697857","repostType":4,"repost":{"id":"1142697857","kind":"news","pubTimestamp":1623752468,"share":"https://ttm.financial/m/news/1142697857?lang=&edition=fundamental","pubTime":"2021-06-15 18:21","market":"us","language":"en","title":"Fed Poised to Crawl Onto ‘Knife Edge’ to Rein In Record Largesse","url":"https://stock-news.laohu8.com/highlight/detail?id=1142697857","media":"Bloomberg","summary":"Fed wants to normalize relations with Congress, markets\nPolicy makers may begin months-long talks on","content":"<ul>\n <li>Fed wants to normalize relations with Congress, markets</li>\n <li>Policy makers may begin months-long talks on taper Tuesday</li>\n</ul>\n<p>The Federal Reserve is inching toward the start of a long road to normalizing its relationship with the rest of Washington and Wall Street.</p>\n<p>After spending the past 15 months providing unprecedented help to the federal government and investors via trillions of dollars of bond purchases, it could start preliminary discussions about scaling back that support at a pivotal two-day policy meeting that kicks off on Tuesday.</p>\n<p>Even so, actual steps in that direction by Chair Jerome Powell and his colleagues are likely still months off.</p>\n<p>Weaning Wall Street and Washington off the Fed’s extraordinary largesse won’t be easy. Since Covid-19 struck the U.S. in March 2020, the central bank has brought more than $2.5 trillion of U.S. Treasury debt, effectively covering more than half of the federal government’s red ink over that time.</p>\n<p><img src=\"https://static.tigerbbs.com/f845f5d5fa4baccad7e30207df549d71\" tg-width=\"620\" tg-height=\"348\">That buying -- together with about $870 billion in purchases of mortgage-backed securities -- has flooded the financial markets with liquidity, contributing to a doubling of the stock market from its pandemic low.</p>\n<p>“It will be like crawling along a knife-edge ridge,” former Bank of England policy maker Charles Goodhart said of the task facing the Fed. “If you do too little you’ll find inflation will just go on accelerating. If you do too much you get into a financial crisis and a recession.”</p>\n<p>Fed officials have said they want to see “substantial further progress” toward their goals of maximum employment and average 2% inflation before reducing current asset purchases of $120 billion per month. None are suggesting that they’re close to achieving that, though some have pressed for discussions to begin on a plan for tapering that buying.</p>\n<p>As Powell has pointed out more than once, payrolls are still substantially below where they were pre-pandemic -- some 7.6 million jobs short, according to the May employment report. And while inflation recently has proven surprisingly rapid -- consumer prices climbed 5% in May from a year earlier -- Powell and other Fed officials have argued that the rise is mostly transitory, the result of temporary bottlenecks as the economy reopens and low readings a year ago when it shut down.</p>\n<p><b>Price Pressures Heat Up</b></p>\n<p>U.S. core and headline inflation both increased more than forecast in May</p>\n<p><img src=\"https://static.tigerbbs.com/320b6b6419ac9bcbe999007f7786196f\" tg-width=\"643\" tg-height=\"330\">“Why would the Fed try to fix bottleneck-driven inflation by signaling earlier rate hikes and hitting demand?” Julia Coronado, president of MacroPolicy Perspectives, asked in a June 14 tweet.</p>\n<p>Instead, after years of falling short of their inflation goal, policy makers will “err on the side of patience” in scaling back stimulus, said former Fed official David Wilcox, who is now at the Peterson Institute for International Economics.</p>\n<p>Powell’s past and potential future also argue for patience. As a Fed governor in 2013, he was among those pushing then-Chairman Ben Bernanke to roll back quantitative easing, only to see the financial markets throw a “taper tantrum” at the mere suggestion such a policy shift was coming.</p>\n<p>With his own term as Fed chair up next February, Powell has an extra incentive to avoid a repeat of such turbulence.</p>\n<p>“While the Fed is an independent institution, its leadership, up for reappointment next year, could not totally ignore the dim view the administration and Democratic Congress would take toward a shift to a more pre-emptive policy stance,” Deutsche Bank chief economist David Folkerts-Landau and colleagues wrote in a June 7 report.</p>\n<p>Some three-quarters of economists surveyed by Bloomberg last week said they expect the Fed to announce between August and year-end that it will begin paring its purchases, with one-third forecasting it won’t fire the starting gun until December.</p>\n<p>It’s not just the timing of the taper that’s up for discussion. So too are its composition and pace.</p>\n<p>The Fed has faced criticism from within and outside the organization for continuing to buy $40 billion of mortgage-backed securities per month while house prices are surging. Vice Chair Randal Quarles said last month that the Fed would “certainly” look at that issue in the context of its taper discussions.</p>\n<p><b>Steady Pace</b></p>\n<p>The last time the Fed wound up a quantitative easing program, in 2014, it shrank its asset purchases at a steady pace.</p>\n<p>“Investors may be lulled into a false sense of security by that experience,” former Fed official William English told a June 8 Deutsche Bank webinar. Given all the uncertainty surrounding the post pandemic economy, “it’s not necessarily going to be the case that the Fed is going to taper in steady steps.”</p>\n<p>Much may depend on the financial markets. American Enterprise Institute resident fellow Desmond Lachman said the ultra-easy monetary policy being pursued by the Fed and other major central banks has led to an “everything asset price bubble,” with stock, credit and housing markets all frothy.</p>\n<p>“The chance of the bubble bursting is all the greater if the Fed is behind the curve,” he said.</p>\n<p>English, who is now at the Yale School of Management, said it’s going to be politically hard for the Fed to wind up its asset purchases and increase interest rates because that will boost the government’s borrowing costs.</p>\n<p>“The Fed is going to come under a lot of criticism for raising rates and making budget choices for the Congress considerably tougher,” he said, adding, “At some level, the Fed needs to both normalize policy but also normalize its relationship with the government.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fed Poised to Crawl Onto ‘Knife Edge’ to Rein In Record Largesse</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFed Poised to Crawl Onto ‘Knife Edge’ to Rein In Record Largesse\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 18:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-15/fed-poised-to-crawl-onto-knife-edge-to-rein-in-record-largesse><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fed wants to normalize relations with Congress, markets\nPolicy makers may begin months-long talks on taper Tuesday\n\nThe Federal Reserve is inching toward the start of a long road to normalizing its ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-15/fed-poised-to-crawl-onto-knife-edge-to-rein-in-record-largesse\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-15/fed-poised-to-crawl-onto-knife-edge-to-rein-in-record-largesse","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142697857","content_text":"Fed wants to normalize relations with Congress, markets\nPolicy makers may begin months-long talks on taper Tuesday\n\nThe Federal Reserve is inching toward the start of a long road to normalizing its relationship with the rest of Washington and Wall Street.\nAfter spending the past 15 months providing unprecedented help to the federal government and investors via trillions of dollars of bond purchases, it could start preliminary discussions about scaling back that support at a pivotal two-day policy meeting that kicks off on Tuesday.\nEven so, actual steps in that direction by Chair Jerome Powell and his colleagues are likely still months off.\nWeaning Wall Street and Washington off the Fed’s extraordinary largesse won’t be easy. Since Covid-19 struck the U.S. in March 2020, the central bank has brought more than $2.5 trillion of U.S. Treasury debt, effectively covering more than half of the federal government’s red ink over that time.\nThat buying -- together with about $870 billion in purchases of mortgage-backed securities -- has flooded the financial markets with liquidity, contributing to a doubling of the stock market from its pandemic low.\n“It will be like crawling along a knife-edge ridge,” former Bank of England policy maker Charles Goodhart said of the task facing the Fed. “If you do too little you’ll find inflation will just go on accelerating. If you do too much you get into a financial crisis and a recession.”\nFed officials have said they want to see “substantial further progress” toward their goals of maximum employment and average 2% inflation before reducing current asset purchases of $120 billion per month. None are suggesting that they’re close to achieving that, though some have pressed for discussions to begin on a plan for tapering that buying.\nAs Powell has pointed out more than once, payrolls are still substantially below where they were pre-pandemic -- some 7.6 million jobs short, according to the May employment report. And while inflation recently has proven surprisingly rapid -- consumer prices climbed 5% in May from a year earlier -- Powell and other Fed officials have argued that the rise is mostly transitory, the result of temporary bottlenecks as the economy reopens and low readings a year ago when it shut down.\nPrice Pressures Heat Up\nU.S. core and headline inflation both increased more than forecast in May\n“Why would the Fed try to fix bottleneck-driven inflation by signaling earlier rate hikes and hitting demand?” Julia Coronado, president of MacroPolicy Perspectives, asked in a June 14 tweet.\nInstead, after years of falling short of their inflation goal, policy makers will “err on the side of patience” in scaling back stimulus, said former Fed official David Wilcox, who is now at the Peterson Institute for International Economics.\nPowell’s past and potential future also argue for patience. As a Fed governor in 2013, he was among those pushing then-Chairman Ben Bernanke to roll back quantitative easing, only to see the financial markets throw a “taper tantrum” at the mere suggestion such a policy shift was coming.\nWith his own term as Fed chair up next February, Powell has an extra incentive to avoid a repeat of such turbulence.\n“While the Fed is an independent institution, its leadership, up for reappointment next year, could not totally ignore the dim view the administration and Democratic Congress would take toward a shift to a more pre-emptive policy stance,” Deutsche Bank chief economist David Folkerts-Landau and colleagues wrote in a June 7 report.\nSome three-quarters of economists surveyed by Bloomberg last week said they expect the Fed to announce between August and year-end that it will begin paring its purchases, with one-third forecasting it won’t fire the starting gun until December.\nIt’s not just the timing of the taper that’s up for discussion. So too are its composition and pace.\nThe Fed has faced criticism from within and outside the organization for continuing to buy $40 billion of mortgage-backed securities per month while house prices are surging. Vice Chair Randal Quarles said last month that the Fed would “certainly” look at that issue in the context of its taper discussions.\nSteady Pace\nThe last time the Fed wound up a quantitative easing program, in 2014, it shrank its asset purchases at a steady pace.\n“Investors may be lulled into a false sense of security by that experience,” former Fed official William English told a June 8 Deutsche Bank webinar. Given all the uncertainty surrounding the post pandemic economy, “it’s not necessarily going to be the case that the Fed is going to taper in steady steps.”\nMuch may depend on the financial markets. American Enterprise Institute resident fellow Desmond Lachman said the ultra-easy monetary policy being pursued by the Fed and other major central banks has led to an “everything asset price bubble,” with stock, credit and housing markets all frothy.\n“The chance of the bubble bursting is all the greater if the Fed is behind the curve,” he said.\nEnglish, who is now at the Yale School of Management, said it’s going to be politically hard for the Fed to wind up its asset purchases and increase interest rates because that will boost the government’s borrowing costs.\n“The Fed is going to come under a lot of criticism for raising rates and making budget choices for the Congress considerably tougher,” he said, adding, “At some level, the Fed needs to both normalize policy but also normalize its relationship with the government.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":189543286,"gmtCreate":1623283148145,"gmtModify":1704199912054,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/189543286","repostId":"2142938243","repostType":4,"repost":{"id":"2142938243","kind":"news","pubTimestamp":1623282600,"share":"https://ttm.financial/m/news/2142938243?lang=&edition=fundamental","pubTime":"2021-06-10 07:50","market":"us","language":"en","title":"1stdibs.com, Inc. Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2142938243","media":"StreetInsider","summary":"NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- 1stdibs.com, Inc. (1stDibs) announced today the pricing ","content":"<p>NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- 1stdibs.com, Inc. (1stDibs) announced today the pricing of its initial public offering of an aggregate of 5,750,000 shares of its common stock at a price to the public of $20.00 per share. The shares are expected to begin trading on The Nasdaq Global Market under the ticker symbol “DIBS” on June 10, 2021. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $115 million, excluding any exercise of the underwriters’ over-allotment option. The offering is expected to close on June 14, 2021, subject to customary closing conditions.</p>\n<p>In addition, 1stDibs has granted the underwriters a 30-day option to purchase up to 862,500 additional shares of common stock at the initial price to the public, less underwriting discounts and commissions.</p>\n<p>BofA Securities and Barclays are acting as joint lead book-running managers, Allen &amp; Company LLC and Evercore ISI are acting as joint bookrunner managers, and William Blair, Raymond James and JMP Securities are acting as co-managers for the offering.</p>\n<p>The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from BofA Securities, Attn: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina, 28255-0001, by email at dg.prospectus_requests@bofa.com; or from Barclays Capital Inc. c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 888-603-5847, or by email at Barclaysprospectus@broadridge.com.</p>\n<p>A registration statement relating to these securities has been filed with, and declared effective on June 9, 2021 by, the U.S. Securities and Exchange Commission. Copies of the registration statement, as amended, can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>About 1stDibs</b></p>\n<p>1stDibs is a leading online marketplace for connecting design lovers with highly coveted sellers and makers of vintage, antique, and contemporary furniture, home décor, art, jewelry, watches and fashion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1stdibs.com, Inc. Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1stdibs.com, Inc. Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 07:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18542205><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- 1stdibs.com, Inc. (1stDibs) announced today the pricing of its initial public offering of an aggregate of 5,750,000 shares of its common stock at a price to...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18542205\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIBS":"1stdibs.com Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18542205","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142938243","content_text":"NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- 1stdibs.com, Inc. (1stDibs) announced today the pricing of its initial public offering of an aggregate of 5,750,000 shares of its common stock at a price to the public of $20.00 per share. The shares are expected to begin trading on The Nasdaq Global Market under the ticker symbol “DIBS” on June 10, 2021. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $115 million, excluding any exercise of the underwriters’ over-allotment option. The offering is expected to close on June 14, 2021, subject to customary closing conditions.\nIn addition, 1stDibs has granted the underwriters a 30-day option to purchase up to 862,500 additional shares of common stock at the initial price to the public, less underwriting discounts and commissions.\nBofA Securities and Barclays are acting as joint lead book-running managers, Allen & Company LLC and Evercore ISI are acting as joint bookrunner managers, and William Blair, Raymond James and JMP Securities are acting as co-managers for the offering.\nThe offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from BofA Securities, Attn: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina, 28255-0001, by email at dg.prospectus_requests@bofa.com; or from Barclays Capital Inc. c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 888-603-5847, or by email at Barclaysprospectus@broadridge.com.\nA registration statement relating to these securities has been filed with, and declared effective on June 9, 2021 by, the U.S. Securities and Exchange Commission. Copies of the registration statement, as amended, can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout 1stDibs\n1stDibs is a leading online marketplace for connecting design lovers with highly coveted sellers and makers of vintage, antique, and contemporary furniture, home décor, art, jewelry, watches and fashion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":189540058,"gmtCreate":1623283060874,"gmtModify":1704199908943,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"Pls like and comment ?","listText":"Pls like and comment ?","text":"Pls like and comment ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/189540058","repostId":"1142408805","repostType":4,"repost":{"id":"1142408805","kind":"news","pubTimestamp":1623280126,"share":"https://ttm.financial/m/news/1142408805?lang=&edition=fundamental","pubTime":"2021-06-10 07:08","market":"us","language":"en","title":"U.S. stocks end lower ahead of inflation report","url":"https://stock-news.laohu8.com/highlight/detail?id=1142408805","media":"reuters","summary":"NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants a","content":"<p>NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish monetary policy.</p>\n<p>The retail “meme stock” craze continued unabated.</p>\n<p>All three major U.S. stock indexes reversed earlier gains, but remained range-bound in the absence of any clear market catalysts.</p>\n<p>“There’s a lull period in terms of news,” said Chuck Carlson, chief executive at Horizon Investment Services in Hammond, Indiana. “We’re through earnings period and people are waiting for inflation numbers tomorrow, so you have a mixed market where the major averages aren’t doing much of anything.”</p>\n<p>Heavily shorted meme stocks extended their social media-driven rally, with Aethlon Medical soaring 388.2%.</p>\n<p>Reddit chatter also helped to lift shares of prison operator GEO Group and World Wrestling Entertainment 38.4% and 10.9%, respectively.</p>\n<p>However, other meme stocks such as Clover Health, AMC Entertainment and Bed Bath &amp; Beyond closed lower.</p>\n<p>Retail volume has returned to its January peak, according to Vanda Research, as social media forums scramble to identify the next GameStop Corp, the stock that kicked off the phenomenon.</p>\n<p>“It feels like alternative stock market,” Carlson added. It’s an indication of speculation. You can be successful if you get in at the right moment but it’s very difficult to play successfully over time.”</p>\n<p>“I don’t think you should read too much regarding the broader market.”</p>\n<p>GameStop named Matt Furlong as its new CEO ahead of its earnings report, which showed a quarterly loss of $1.01 per share. Its shares fell over 4% in after-hours trading.</p>\n<p>U.S. President Joe Biden changed course in ongoing negotiations to reach a bipartisan agreement on infrastructure spending after one-on-one talks with Senator Shelley Capito broke down.</p>\n<p>Industrial stocks, which stand to benefit from an infrastructure deal, slid by 1%.</p>\n<p>Washington lawmakers passed a sweeping bill designed to boost the United States’ ability to compete against Chinese technology, providing funds for research and semiconductor production amid an ongoing chip supply drought. The bill now heads to the House of Representatives.</p>\n<p>Even so, the Philadelphia SE Semiconductor index slipped 0.4%.</p>\n<p>The Labor Department’s consumer price index report due out Thursday will provide another take on inflation amid the recovery’s demand/supply imbalance as investors determine whether inflationary pressures, as the Fed asserts, will be transitory.</p>\n<p>The Dow Jones Industrial Average fell 152.68 points, or 0.44%, to 34,447.14; the S&amp;P 500 lost 7.71 points, or 0.18%, at 4,219.55; and the Nasdaq Composite dropped 13.16 points, or 0.09%, to 13,911.75.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare gained the most.</p>\n<p>Benchmark Treasury yields dropped below 1.5% for the first time since May, weighing on interest-sensitive financials.</p>\n<p>Campbell Soup Co missed quarterly profit expectations and slashed its full-year earnings forecast, sending its shares down 6.5%.</p>\n<p>Drugmaker Merck &amp; Co rose 2.3% on the heels of its announcement the U.S. government had agreed to buy about 1.7 million courses of the company’s experimental COVID-19 treatment, molnupiravir, for about $1.2 billion, if the drug meets regulatory approval.</p>\n<p>Declining issues outnumbered advancers on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.13-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 38 new 52-week highs and two new lows; the Nasdaq Composite recorded 126 new highs and 14 new lows.</p>\n<p>Volume on U.S. exchanges was 11.53 billion shares, compared with the 10.74 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks end lower ahead of inflation report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks end lower ahead of inflation report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AEMD":"Aethlon Medical Inc",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142408805","content_text":"NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish monetary policy.\nThe retail “meme stock” craze continued unabated.\nAll three major U.S. stock indexes reversed earlier gains, but remained range-bound in the absence of any clear market catalysts.\n“There’s a lull period in terms of news,” said Chuck Carlson, chief executive at Horizon Investment Services in Hammond, Indiana. “We’re through earnings period and people are waiting for inflation numbers tomorrow, so you have a mixed market where the major averages aren’t doing much of anything.”\nHeavily shorted meme stocks extended their social media-driven rally, with Aethlon Medical soaring 388.2%.\nReddit chatter also helped to lift shares of prison operator GEO Group and World Wrestling Entertainment 38.4% and 10.9%, respectively.\nHowever, other meme stocks such as Clover Health, AMC Entertainment and Bed Bath & Beyond closed lower.\nRetail volume has returned to its January peak, according to Vanda Research, as social media forums scramble to identify the next GameStop Corp, the stock that kicked off the phenomenon.\n“It feels like alternative stock market,” Carlson added. It’s an indication of speculation. You can be successful if you get in at the right moment but it’s very difficult to play successfully over time.”\n“I don’t think you should read too much regarding the broader market.”\nGameStop named Matt Furlong as its new CEO ahead of its earnings report, which showed a quarterly loss of $1.01 per share. Its shares fell over 4% in after-hours trading.\nU.S. President Joe Biden changed course in ongoing negotiations to reach a bipartisan agreement on infrastructure spending after one-on-one talks with Senator Shelley Capito broke down.\nIndustrial stocks, which stand to benefit from an infrastructure deal, slid by 1%.\nWashington lawmakers passed a sweeping bill designed to boost the United States’ ability to compete against Chinese technology, providing funds for research and semiconductor production amid an ongoing chip supply drought. The bill now heads to the House of Representatives.\nEven so, the Philadelphia SE Semiconductor index slipped 0.4%.\nThe Labor Department’s consumer price index report due out Thursday will provide another take on inflation amid the recovery’s demand/supply imbalance as investors determine whether inflationary pressures, as the Fed asserts, will be transitory.\nThe Dow Jones Industrial Average fell 152.68 points, or 0.44%, to 34,447.14; the S&P 500 lost 7.71 points, or 0.18%, at 4,219.55; and the Nasdaq Composite dropped 13.16 points, or 0.09%, to 13,911.75.\nAmong the 11 major sectors in the S&P 500, healthcare gained the most.\nBenchmark Treasury yields dropped below 1.5% for the first time since May, weighing on interest-sensitive financials.\nCampbell Soup Co missed quarterly profit expectations and slashed its full-year earnings forecast, sending its shares down 6.5%.\nDrugmaker Merck & Co rose 2.3% on the heels of its announcement the U.S. government had agreed to buy about 1.7 million courses of the company’s experimental COVID-19 treatment, molnupiravir, for about $1.2 billion, if the drug meets regulatory approval.\nDeclining issues outnumbered advancers on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.13-to-1 ratio favored decliners.\nThe S&P 500 posted 38 new 52-week highs and two new lows; the Nasdaq Composite recorded 126 new highs and 14 new lows.\nVolume on U.S. exchanges was 11.53 billion shares, compared with the 10.74 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117163297,"gmtCreate":1623123282119,"gmtModify":1704196561131,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"Comment pls!","listText":"Comment pls!","text":"Comment pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/117163297","repostId":"2141342255","repostType":4,"repost":{"id":"2141342255","kind":"news","pubTimestamp":1623098661,"share":"https://ttm.financial/m/news/2141342255?lang=&edition=fundamental","pubTime":"2021-06-08 04:44","market":"us","language":"en","title":"S&P closes nominally lower as investors wait for a catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2141342255","media":"REUTERS","summary":"NEW YORK (REUTERS) - The S&P 500 ended a languid session slightly in the red on Monday (June 7), wit","content":"<div>\n<p>NEW YORK (REUTERS) - The S&P 500 ended a languid session slightly in the red on Monday (June 7), with investors standing by on news of a global minimum corporate tax rate, lingering inflation fears, ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/sp-closes-nominally-lower-as-investors-wait-for-a-catalyst\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P closes nominally lower as investors wait for a catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P closes nominally lower as investors wait for a catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 04:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/business/companies-markets/sp-closes-nominally-lower-as-investors-wait-for-a-catalyst><strong>REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (REUTERS) - The S&P 500 ended a languid session slightly in the red on Monday (June 7), with investors standing by on news of a global minimum corporate tax rate, lingering inflation fears, ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/sp-closes-nominally-lower-as-investors-wait-for-a-catalyst\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OEX":"标普100","UPRO":"三倍做多标普500ETF",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","BIIB":"渤健公司","SSO":"两倍做多标普500ETF","OEF":"标普100指数ETF-iShares","SH":"标普500反向ETF","SPXU":"三倍做空标普500ETF","IVV":"标普500指数ETF"},"source_url":"http://www.straitstimes.com/business/companies-markets/sp-closes-nominally-lower-as-investors-wait-for-a-catalyst","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141342255","content_text":"NEW YORK (REUTERS) - The S&P 500 ended a languid session slightly in the red on Monday (June 7), with investors standing by on news of a global minimum corporate tax rate, lingering inflation fears, and a lack of market-moving economic news.The Dow closed well within negative territory, while the Nasdaq advanced. Still, the S&P and the Dow remained inside one percentage point of their record closing highs.\"Thematically, we're done with earnings, so you have this lull in between earnings when what drives the market is economic data points,\" said Joseph Sroka, chief investment officer at NovaPoint in Atlanta. \"There's not a lot of impetus for investors to take action today.\"\"There's been this flip-flop between whether inflation will be transitory or persistent, and the next card that gets flipped over for that is the CPI report on Thursday,\" Sroka added.Small-caps outperformed as the ongoing retail frenzy boosted stocks whose recent explosive trading volumes have been attributed to social media buzz.AMC Entertainment Holdings jumped 14.8%, extending the previous week's 85% gain.Other so-called \"meme stocks,\" including GameStop and US-listed shares of Blackberry advanced between 7% and 14%.\"You've seen a decades-long, technology-enabled democratisation of the market and there's certainly groups of individual investors that flock to these ideas,\" Sroka said. \"We're seeing speculative trading in an age of multiple outlets and social media amplifies the news.\"The Group of Seven (G-7) advanced economies agreed on Saturday to back a minimum global corporate tax rate of at least 15%, a move Treasury Secretary Janet Yellen called a \"significant, unprecedented commitment\" to bring what she called a race to the bottom on global taxation.Lawmakers in Washington are doubling down on efforts to craft a bipartisan infrastructure spending package, with House Democrats expected to bring a bill to vote as early as Wednesday.The Dow Jones Industrial Average fell 126.15 points, or 0.36%, to 34,630.24; the S&P 500 lost 3.37 points, or 0.08%, at 4,226.52; and the Nasdaq Composite added 67.23 points, or 0.49%, at 13,881.72.Of the 11 major sectors in the S&P 500, seven lost ground, with materials suffering the largest percentage drop.Real estate led the gainers.Shares of Biogen Inc surged 38.3% following news that the US Food and Drug Administration approved its Alzheimer's disease drug aducanumab.Data centre operator QTS Realty Trust jumped 21.2% on reports of a takeover deal by investment firm Blackstone Group worth $6.7 billion. Cruise operator Royal Caribbean announced that six of its ships would begin sailing from Florida and Texas ports in July and August.Its shares gained 0.4%, while rivals Carnival and Norwegian Cruise Line advanced 1.1% and 3.1%, respectively.Advancing issues outnumbered decliners on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.82-to-1 ratio favored advancers.The S&P 500 posted 62 new 52-week highs and one new low; the Nasdaq Composite recorded 168 new highs and 21 new lows.Volume on U.S. exchanges was 10.52 billion shares, compared with the 10.71 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117169226,"gmtCreate":1623123180365,"gmtModify":1704196559664,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"Happy to read this news","listText":"Happy to read this news","text":"Happy to read this news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/117169226","repostId":"2141453253","repostType":4,"repost":{"id":"2141453253","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623096780,"share":"https://ttm.financial/m/news/2141453253?lang=&edition=fundamental","pubTime":"2021-06-08 04:13","market":"us","language":"en","title":"Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK","url":"https://stock-news.laohu8.com/highlight/detail?id=2141453253","media":"Dow Jones","summary":"Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of","content":"<p>Shares rally to second -biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day percentage gain since they went public 30 years ago</p><p>Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.</p><p>The stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.</p><p>Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.</p><p>Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.</p><p>Biogen investors were treated to the stock's biggest-ever <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"</p><p>\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"</p><p>As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.</p><p>Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"</p><p>Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"</p><p>Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.</p><p>\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"</p><p>Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.</p><p>Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .</p><p>Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.</p><p>Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.</p><p>Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.</p><p>Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.</p><p>Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.</p><p>\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.</p><p>Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has gained 8.0% and the S&amp;P 500 index  has advanced 12.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-08 04:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares rally to second -biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day percentage gain since they went public 30 years ago</p><p>Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.</p><p>The stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.</p><p>Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.</p><p>Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.</p><p>Biogen investors were treated to the stock's biggest-ever <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"</p><p>\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"</p><p>As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.</p><p>Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"</p><p>Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"</p><p>Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.</p><p>\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"</p><p>Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.</p><p>Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .</p><p>Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.</p><p>Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.</p><p>Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.</p><p>Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.</p><p>Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.</p><p>\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.</p><p>Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has gained 8.0% and the S&amp;P 500 index  has advanced 12.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141453253","content_text":"Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.The stock $(BIIB)$ blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.Biogen investors were treated to the stock's biggest-ever one-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund $(XLV)$ has gained 8.0% and the S&P 500 index  has advanced 12.5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":117163297,"gmtCreate":1623123282119,"gmtModify":1704196561131,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"Comment pls!","listText":"Comment pls!","text":"Comment pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/117163297","repostId":"2141342255","repostType":4,"repost":{"id":"2141342255","kind":"news","pubTimestamp":1623098661,"share":"https://ttm.financial/m/news/2141342255?lang=&edition=fundamental","pubTime":"2021-06-08 04:44","market":"us","language":"en","title":"S&P closes nominally lower as investors wait for a catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2141342255","media":"REUTERS","summary":"NEW YORK (REUTERS) - The S&P 500 ended a languid session slightly in the red on Monday (June 7), wit","content":"<div>\n<p>NEW YORK (REUTERS) - The S&P 500 ended a languid session slightly in the red on Monday (June 7), with investors standing by on news of a global minimum corporate tax rate, lingering inflation fears, ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/sp-closes-nominally-lower-as-investors-wait-for-a-catalyst\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P closes nominally lower as investors wait for a catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P closes nominally lower as investors wait for a catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 04:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/business/companies-markets/sp-closes-nominally-lower-as-investors-wait-for-a-catalyst><strong>REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (REUTERS) - The S&P 500 ended a languid session slightly in the red on Monday (June 7), with investors standing by on news of a global minimum corporate tax rate, lingering inflation fears, ...</p>\n\n<a href=\"http://www.straitstimes.com/business/companies-markets/sp-closes-nominally-lower-as-investors-wait-for-a-catalyst\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OEX":"标普100","UPRO":"三倍做多标普500ETF",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","BIIB":"渤健公司","SSO":"两倍做多标普500ETF","OEF":"标普100指数ETF-iShares","SH":"标普500反向ETF","SPXU":"三倍做空标普500ETF","IVV":"标普500指数ETF"},"source_url":"http://www.straitstimes.com/business/companies-markets/sp-closes-nominally-lower-as-investors-wait-for-a-catalyst","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141342255","content_text":"NEW YORK (REUTERS) - The S&P 500 ended a languid session slightly in the red on Monday (June 7), with investors standing by on news of a global minimum corporate tax rate, lingering inflation fears, and a lack of market-moving economic news.The Dow closed well within negative territory, while the Nasdaq advanced. Still, the S&P and the Dow remained inside one percentage point of their record closing highs.\"Thematically, we're done with earnings, so you have this lull in between earnings when what drives the market is economic data points,\" said Joseph Sroka, chief investment officer at NovaPoint in Atlanta. \"There's not a lot of impetus for investors to take action today.\"\"There's been this flip-flop between whether inflation will be transitory or persistent, and the next card that gets flipped over for that is the CPI report on Thursday,\" Sroka added.Small-caps outperformed as the ongoing retail frenzy boosted stocks whose recent explosive trading volumes have been attributed to social media buzz.AMC Entertainment Holdings jumped 14.8%, extending the previous week's 85% gain.Other so-called \"meme stocks,\" including GameStop and US-listed shares of Blackberry advanced between 7% and 14%.\"You've seen a decades-long, technology-enabled democratisation of the market and there's certainly groups of individual investors that flock to these ideas,\" Sroka said. \"We're seeing speculative trading in an age of multiple outlets and social media amplifies the news.\"The Group of Seven (G-7) advanced economies agreed on Saturday to back a minimum global corporate tax rate of at least 15%, a move Treasury Secretary Janet Yellen called a \"significant, unprecedented commitment\" to bring what she called a race to the bottom on global taxation.Lawmakers in Washington are doubling down on efforts to craft a bipartisan infrastructure spending package, with House Democrats expected to bring a bill to vote as early as Wednesday.The Dow Jones Industrial Average fell 126.15 points, or 0.36%, to 34,630.24; the S&P 500 lost 3.37 points, or 0.08%, at 4,226.52; and the Nasdaq Composite added 67.23 points, or 0.49%, at 13,881.72.Of the 11 major sectors in the S&P 500, seven lost ground, with materials suffering the largest percentage drop.Real estate led the gainers.Shares of Biogen Inc surged 38.3% following news that the US Food and Drug Administration approved its Alzheimer's disease drug aducanumab.Data centre operator QTS Realty Trust jumped 21.2% on reports of a takeover deal by investment firm Blackstone Group worth $6.7 billion. Cruise operator Royal Caribbean announced that six of its ships would begin sailing from Florida and Texas ports in July and August.Its shares gained 0.4%, while rivals Carnival and Norwegian Cruise Line advanced 1.1% and 3.1%, respectively.Advancing issues outnumbered decliners on the NYSE by a 1.35-to-1 ratio; on Nasdaq, a 1.82-to-1 ratio favored advancers.The S&P 500 posted 62 new 52-week highs and one new low; the Nasdaq Composite recorded 168 new highs and 21 new lows.Volume on U.S. exchanges was 10.52 billion shares, compared with the 10.71 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":189540058,"gmtCreate":1623283060874,"gmtModify":1704199908943,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"Pls like and comment ?","listText":"Pls like and comment ?","text":"Pls like and comment ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/189540058","repostId":"1142408805","repostType":4,"repost":{"id":"1142408805","kind":"news","pubTimestamp":1623280126,"share":"https://ttm.financial/m/news/1142408805?lang=&edition=fundamental","pubTime":"2021-06-10 07:08","market":"us","language":"en","title":"U.S. stocks end lower ahead of inflation report","url":"https://stock-news.laohu8.com/highlight/detail?id=1142408805","media":"reuters","summary":"NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants a","content":"<p>NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish monetary policy.</p>\n<p>The retail “meme stock” craze continued unabated.</p>\n<p>All three major U.S. stock indexes reversed earlier gains, but remained range-bound in the absence of any clear market catalysts.</p>\n<p>“There’s a lull period in terms of news,” said Chuck Carlson, chief executive at Horizon Investment Services in Hammond, Indiana. “We’re through earnings period and people are waiting for inflation numbers tomorrow, so you have a mixed market where the major averages aren’t doing much of anything.”</p>\n<p>Heavily shorted meme stocks extended their social media-driven rally, with Aethlon Medical soaring 388.2%.</p>\n<p>Reddit chatter also helped to lift shares of prison operator GEO Group and World Wrestling Entertainment 38.4% and 10.9%, respectively.</p>\n<p>However, other meme stocks such as Clover Health, AMC Entertainment and Bed Bath &amp; Beyond closed lower.</p>\n<p>Retail volume has returned to its January peak, according to Vanda Research, as social media forums scramble to identify the next GameStop Corp, the stock that kicked off the phenomenon.</p>\n<p>“It feels like alternative stock market,” Carlson added. It’s an indication of speculation. You can be successful if you get in at the right moment but it’s very difficult to play successfully over time.”</p>\n<p>“I don’t think you should read too much regarding the broader market.”</p>\n<p>GameStop named Matt Furlong as its new CEO ahead of its earnings report, which showed a quarterly loss of $1.01 per share. Its shares fell over 4% in after-hours trading.</p>\n<p>U.S. President Joe Biden changed course in ongoing negotiations to reach a bipartisan agreement on infrastructure spending after one-on-one talks with Senator Shelley Capito broke down.</p>\n<p>Industrial stocks, which stand to benefit from an infrastructure deal, slid by 1%.</p>\n<p>Washington lawmakers passed a sweeping bill designed to boost the United States’ ability to compete against Chinese technology, providing funds for research and semiconductor production amid an ongoing chip supply drought. The bill now heads to the House of Representatives.</p>\n<p>Even so, the Philadelphia SE Semiconductor index slipped 0.4%.</p>\n<p>The Labor Department’s consumer price index report due out Thursday will provide another take on inflation amid the recovery’s demand/supply imbalance as investors determine whether inflationary pressures, as the Fed asserts, will be transitory.</p>\n<p>The Dow Jones Industrial Average fell 152.68 points, or 0.44%, to 34,447.14; the S&amp;P 500 lost 7.71 points, or 0.18%, at 4,219.55; and the Nasdaq Composite dropped 13.16 points, or 0.09%, to 13,911.75.</p>\n<p>Among the 11 major sectors in the S&amp;P 500, healthcare gained the most.</p>\n<p>Benchmark Treasury yields dropped below 1.5% for the first time since May, weighing on interest-sensitive financials.</p>\n<p>Campbell Soup Co missed quarterly profit expectations and slashed its full-year earnings forecast, sending its shares down 6.5%.</p>\n<p>Drugmaker Merck &amp; Co rose 2.3% on the heels of its announcement the U.S. government had agreed to buy about 1.7 million courses of the company’s experimental COVID-19 treatment, molnupiravir, for about $1.2 billion, if the drug meets regulatory approval.</p>\n<p>Declining issues outnumbered advancers on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.13-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 38 new 52-week highs and two new lows; the Nasdaq Composite recorded 126 new highs and 14 new lows.</p>\n<p>Volume on U.S. exchanges was 11.53 billion shares, compared with the 10.74 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks end lower ahead of inflation report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks end lower ahead of inflation report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AEMD":"Aethlon Medical Inc",".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-u-s-stocks-end-lower-ahead-of-inflation-report-idUSL2N2NR2UG","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142408805","content_text":"NEW YORK (Reuters) - Wall Street ended a see-saw session lower on Wednesday as market participants awaited inflation data for clues as to when the U.S. Federal Reserve might tighten its dovish monetary policy.\nThe retail “meme stock” craze continued unabated.\nAll three major U.S. stock indexes reversed earlier gains, but remained range-bound in the absence of any clear market catalysts.\n“There’s a lull period in terms of news,” said Chuck Carlson, chief executive at Horizon Investment Services in Hammond, Indiana. “We’re through earnings period and people are waiting for inflation numbers tomorrow, so you have a mixed market where the major averages aren’t doing much of anything.”\nHeavily shorted meme stocks extended their social media-driven rally, with Aethlon Medical soaring 388.2%.\nReddit chatter also helped to lift shares of prison operator GEO Group and World Wrestling Entertainment 38.4% and 10.9%, respectively.\nHowever, other meme stocks such as Clover Health, AMC Entertainment and Bed Bath & Beyond closed lower.\nRetail volume has returned to its January peak, according to Vanda Research, as social media forums scramble to identify the next GameStop Corp, the stock that kicked off the phenomenon.\n“It feels like alternative stock market,” Carlson added. It’s an indication of speculation. You can be successful if you get in at the right moment but it’s very difficult to play successfully over time.”\n“I don’t think you should read too much regarding the broader market.”\nGameStop named Matt Furlong as its new CEO ahead of its earnings report, which showed a quarterly loss of $1.01 per share. Its shares fell over 4% in after-hours trading.\nU.S. President Joe Biden changed course in ongoing negotiations to reach a bipartisan agreement on infrastructure spending after one-on-one talks with Senator Shelley Capito broke down.\nIndustrial stocks, which stand to benefit from an infrastructure deal, slid by 1%.\nWashington lawmakers passed a sweeping bill designed to boost the United States’ ability to compete against Chinese technology, providing funds for research and semiconductor production amid an ongoing chip supply drought. The bill now heads to the House of Representatives.\nEven so, the Philadelphia SE Semiconductor index slipped 0.4%.\nThe Labor Department’s consumer price index report due out Thursday will provide another take on inflation amid the recovery’s demand/supply imbalance as investors determine whether inflationary pressures, as the Fed asserts, will be transitory.\nThe Dow Jones Industrial Average fell 152.68 points, or 0.44%, to 34,447.14; the S&P 500 lost 7.71 points, or 0.18%, at 4,219.55; and the Nasdaq Composite dropped 13.16 points, or 0.09%, to 13,911.75.\nAmong the 11 major sectors in the S&P 500, healthcare gained the most.\nBenchmark Treasury yields dropped below 1.5% for the first time since May, weighing on interest-sensitive financials.\nCampbell Soup Co missed quarterly profit expectations and slashed its full-year earnings forecast, sending its shares down 6.5%.\nDrugmaker Merck & Co rose 2.3% on the heels of its announcement the U.S. government had agreed to buy about 1.7 million courses of the company’s experimental COVID-19 treatment, molnupiravir, for about $1.2 billion, if the drug meets regulatory approval.\nDeclining issues outnumbered advancers on the NYSE by a 1.12-to-1 ratio; on Nasdaq, a 1.13-to-1 ratio favored decliners.\nThe S&P 500 posted 38 new 52-week highs and two new lows; the Nasdaq Composite recorded 126 new highs and 14 new lows.\nVolume on U.S. exchanges was 11.53 billion shares, compared with the 10.74 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187674824,"gmtCreate":1623753904268,"gmtModify":1704210577461,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/187674824","repostId":"1142697857","repostType":4,"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":189543286,"gmtCreate":1623283148145,"gmtModify":1704199912054,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/189543286","repostId":"2142938243","repostType":4,"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":117169226,"gmtCreate":1623123180365,"gmtModify":1704196559664,"author":{"id":"3579400009595208","authorId":"3579400009595208","name":"Ahchiabor","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579400009595208","authorIdStr":"3579400009595208"},"themes":[],"htmlText":"Happy to read this news","listText":"Happy to read this news","text":"Happy to read this news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/117169226","repostId":"2141453253","repostType":4,"repost":{"id":"2141453253","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623096780,"share":"https://ttm.financial/m/news/2141453253?lang=&edition=fundamental","pubTime":"2021-06-08 04:13","market":"us","language":"en","title":"Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK","url":"https://stock-news.laohu8.com/highlight/detail?id=2141453253","media":"Dow Jones","summary":"Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of","content":"<p>Shares rally to second -biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day percentage gain since they went public 30 years ago</p><p>Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.</p><p>The stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.</p><p>Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.</p><p>Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.</p><p>Biogen investors were treated to the stock's biggest-ever <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"</p><p>\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"</p><p>As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.</p><p>Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"</p><p>Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"</p><p>Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.</p><p>\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"</p><p>Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.</p><p>Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .</p><p>Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.</p><p>Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.</p><p>Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.</p><p>Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.</p><p>Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.</p><p>\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.</p><p>Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has gained 8.0% and the S&amp;P 500 index  has advanced 12.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-08 04:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares rally to second -biggest <a href=\"https://laohu8.com/S/AONE\">one</a>-day percentage gain since they went public 30 years ago</p><p>Shares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.</p><p>The stock <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.</p><p>Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.</p><p>Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.</p><p>Biogen investors were treated to the stock's biggest-ever <a href=\"https://laohu8.com/S/AONE.U\">one</a>-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"</p><p>\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"</p><p>As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.</p><p>Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"</p><p>Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"</p><p>Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.</p><p>\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"</p><p>Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.</p><p>Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .</p><p>Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.</p><p>Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.</p><p>Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.</p><p>Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.</p><p>Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.</p><p>\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.</p><p>Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund <a href=\"https://laohu8.com/S/XLV\">$(XLV)$</a> has gained 8.0% and the S&amp;P 500 index  has advanced 12.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141453253","content_text":"Shares rally to second -biggest one-day percentage gain since they went public 30 years agoShares of Biogen Inc. rocketed to a six-year high in volatile trading Monday, as Wall Street analysts cheered the U.S. Food and Drug Administration's broad labeling that came with the approval of the biotechnology company's Alzheimer's drug.The stock $(BIIB)$ blasted $109.71, or 38.3% higher, to $395.85, the highest close since April 2015. The stock had been halted twice for volatility  during Monday's session, once at 10:44 a.m. Eastern and a second time at 1:37 p.m.Trading volume spiked up to 17.7 million shares, compared with the full-day average over the past 30 days of about 1.0 million shares, according to FactSet.Earlier Friday, the FDA approved Biogen's Aduhelm , also known as aducanumab, to treat Alzheimer's, the first drug to be approved that promises to actually slow the disease rather than just treat the symptoms.Biogen investors were treated to the stock's biggest-ever one-day price gain, and second-biggest one-day percentage gain since it went public in September 1991. The stock had shot up $108.62, or 44.0%, on Nov. 4, 2020, after the FDA said there was \"substantial evidence\"\"Currently available options only treat symptoms of the disease; this treatment option is the first therapy to target and affect the underlying disease process of Alzheimer's,\" said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. \"As we have learned from the fight against cancer, the accelerated approval pathway can bring therapies to patients faster while spurring more research an innovation.\"As the FDA described, accelerated approval can be based on the drug's effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients, with \"a required post-approval trial\" to verify the drug provides that expected clinical benefit.Bernstein analyst Aaron Gal said approval under accelerated pathway is a distinction without a difference. \"The pathway allows for approval based on surrogate market, rather than completed efficacy endpoint data,\" Gal wrote in a note to clients. \"As long as Biogen does not challenge the use of the path, which they obviously would not, the approval holds.\"Evercore ISI's Umer Raffat noted that the option of Accelerated Approval was not discussed by the FDA's advisory committee. And as the drug has \"clearly shown\" in all trials to substantially reduce amyloid beta plaques, the \"reduction in plaques is reasonably likely to result in clinical benefit.\"Regarding labeling, Bernstein's Gal said it is \"almost shockingly broad,\" as the label just said Aduhelm is indicated for the treatment of Alzheimer's disease.\"Thus, the approved population is broader than the tested population (mild-moderate Alzheimer's patients),\" Gal wrote. \"There is also no restriction on treatment duration suggesting that patients can stay on treatment until either all plaque is removed or the patient progresses.\"Evercore's Raffat concurred, saying the label reads very very broad. He indicated that investors could be relieved, as there was some concern that the target population might be limited, and/or require very frequent monitoring.Although pricing is still unknown, the Institute of Clinical and Economic Review (ICER) said that due to the relatively small overall health gains demonstrated in Phase 3 clinical trials, the drug should be price no higher than $8,400 a year, as MarketWatch's Jaimy Lee reported .Some analysts say Biogen could price the drug higher than that, even though that might potentially trigger a regulatory response.Evercore's Raffat said his financial estimates on Biogen include an estimate of $10,000, while Bernstein's Gal said the pricing could end up \"much higher,\" possibly as high as more than $30,000.Gal said Biogen has a long history of pricing drugs in the \"specialty\" range, and is less likely to fear a backlash. \"Biogen would justify the price by arguing the total system impact would be modest upfront and that it will use the money to provide substantial services to [Alzheimer's disease] patients,\" Gal wrote.Biogen and Eisai Inc., the U.S. subsidiary of Japan-based Eisai Co. Ltd. (4523.TO), announced after Aduhelm's approval programs intended to support access for all qualified patients, including those from traditionally underserved populations.Eisai's U.S.-listed shares skyrocketed 68.9% in afternoon trading, on track for a record close and the biggest one-day gain since it started trading in the U.S. in December 1995.\"We are committed to access and health equity as top priorities and will continue working with multiple stakeholders with the goal of helping patients who may benefit from treatment obtain care as quickly as possible,\" said Alisha Alaimo, president of Biogen U.S.Biogen's stock has now run up 61.7% year to date, while SPDR Health Care Select Sector exchange-traded fund $(XLV)$ has gained 8.0% and the S&P 500 index  has advanced 12.5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}